On this basis, we performed an association analysis between the baseline clinical (i.e., hemoglobin, albumin and NLR values and metastatic status) and nutritional variables (i.e., FAACT total score, VAS score for appetite loss and MNA®-based nutritional status) of cancer patients included in the prospective PreMiO study and their clinical outcomes (i.e., rehospitalization, onset of treatment-related toxicity, death, and disease progression) determined at the date of data cut-off of the retrospective NUTRIONCO study after patients’ follow-up. This evidence concerns the gene ALB and cancer.